Omega Stock Today


USD 4.94  0.27  5.78%   

Market Performance
10 of 100
Odds Of Distress
Less than 31
Omega Therapeutics is trading at 4.94 as of the 12th of August 2022, a 5.78 percent increase since the beginning of the trading day. The stock's open price was 4.67. Omega Therapeutics has about a 31 percent probability of financial distress in the next few years of operation but had a somewhat ok performance during the last 90 days. Equity ratings for Omega Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2021 and ending today, the 12th of August 2022. Click here to learn more.
Fiscal Year End
IPO Date
30th of July 2021
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 47.77 M outstanding shares of which 538.79 K shares are now shorted by private and institutional investors with about 2.07 trading days to cover. More on Omega Therapeutics

Moving together with Omega Therapeutics

0.8MRNAModerna Potential GrowthPairCorr
0.88EDITEditas Medicine Normal TradingPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Omega Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Omega Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Omega Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Omega Therapeutics is way too risky over 90 days horizon
Omega Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 412 K. Net Loss for the year was (74.96 M) with loss before overhead, payroll, taxes, and interest of (47.72 M).
Omega Therapeutics currently holds about 200.8 M in cash with (70.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.2.
Over 91.0% of the company shares are owned by institutional investors
Latest headline from Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference -
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Omega Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldOvervalued
Omega Therapeutics (OMGA) is traded on NASDAQ Exchange in USA and employs 79 people. The company currently falls under 'Small-Cap' category with current market capitalization of 235.05 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Omega Therapeutics's market, we take the total number of its shares issued and multiply it by Omega Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Omega Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 47.77 M outstanding shares of which 538.79 K shares are now shorted by private and institutional investors with about 2.07 trading days to cover. Omega Therapeutics currently holds about 200.8 M in cash with (70.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.2.
Check Omega Therapeutics Probability Of Bankruptcy
Omega Therapeutics owns a total of fourty-seven million seven hundred seventy thousand outstanding shares. The majority of Omega Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Omega Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Omega Therapeutics. Please pay attention to any change in the institutional holdings of Omega Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Omega Ownership Details

Omega Stock Price Odds Analysis

What are Omega Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Omega Therapeutics jumping above the current price in 90 days from now is about 12.1%. The Omega Therapeutics probability density function shows the probability of Omega Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.2004. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Omega Therapeutics will likely underperform. Moreover, the company has an alpha of 1.1682, implying that it can generate a 1.17 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 4.94HorizonTargetOdds Above 4.94
87.85%90 days
Based on a normal probability distribution, the odds of Omega Therapeutics to move above the current price in 90 days from now is about 12.1 (This Omega Therapeutics probability density function shows the probability of Omega Stock to fall within a particular range of prices over 90 days) .

Omega Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Omega Therapeutics market risk premium is the additional return an investor will receive from holding Omega Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Omega Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Omega Therapeutics' alpha and beta are two of the key measurements used to evaluate Omega Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Omega Stock Against Markets

Picking the right benchmark for Omega Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Omega Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Omega Therapeutics is critical whether you are bullish or bearish towards Omega Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Omega Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Tickers Now


Stock Tickers

Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
All  Next Launch Module

Invested in Omega Therapeutics?

You need to understand the risk of investing before taking a position in Omega Therapeutics. The danger of trading Omega Therapeutics is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Omega Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Omega Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Omega Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Your Equity Center. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Omega Stock analysis

When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bond Directory
Find actively traded corporate debentures issued by US companies
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
233 M
Return On Assets
Return On Equity
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.